PCI Pharma Services

Based in the US, PCI Pharma Services operates as a contract development and manufacturing organization (CDMO), providing comprehensive solutions for the delivery of injectable drug products. PCI Pharma Services, founded in 2012, is a contract development and manufacturing organization located in Philadelphia, US, specializing in injectable drug products. The company has engaged in 6 deals, with its most recent deal occurring on July 14, 2025, during which it secured a Secondary Buyout of USD 3000. 00 mn led by Kohlberg & Company and Mubadala Investment Company, raising a total of USD 3000.

00 mn to date. Salim Haffar serves as the CEO. PCI Pharma Services specializes in contract development and manufacturing organization (CDMO) services, offering a comprehensive suite of solutions aimed at enhancing the delivery of injectable drug products. The company’s core product offerings include advanced drug delivery systems, drug-device combination products, clinical trial services, and commercial packaging.

These solutions are designed to streamline the drug development process from early-stage development through to commercialization, effectively addressing the needs of pharmaceutical and biotechnology companies. PCI serves a diverse client base, including well-established multinational pharmaceutical companies and emerging biotech firms, focusing on both conventional and specialty injectable therapies. Their services are marketed primarily to North America, Europe, and Asia Pacific, reflecting a broad geographical footprint in the global pharmaceutical landscape. The revenue model for PCI Pharma Services is structured around a B2B framework, where transactions primarily occur through partnerships with pharmaceutical and biotechnology companies.

Clients engage the company for its extensive CDMO services, often entering into contractual agreements that outline specific deliverables related to drug development and manufacturing. Transactions typically involve service fees based on the scope and complexity of the projects, which may include fixed fees for clinical trial services or tiered pricing for commercial production. The company’s flagship services, such as advanced drug delivery and drug-device combination products, play a pivotal role in driving revenue, underscoring PCI's commitment to delivering high-quality solutions tailored to client needs. In July 2025, a consortium led by Bain Capital and Kohlberg & Company, along with Mubadala Investment Company, agreed to acquire a majority stake in PCI Pharma Services.

This acquisition is expected to enable PCI Pharma Services to accelerate its growth plans with the support of Bain Capital. The company is likely to focus on launching new products designed to enhance injectable drug delivery and plans to expand its services into European and Asian markets by the end of 2025.